Uncategorized

$CIIX a First Mover in CBD Skin Care

October 12, 2017

  • China is the second-largest global cosmetics consumer, representing $30 billion annually
  • Savvy industry veteran recruited for vast untapped CBD skin care market
  • 100% of cannabis skin care product market in China up for grabs

It comes as little surprise that cannabidiol (CBD) likely possesses skin healing properties. Found in the marijuana plant, CBD is one of over 80 natural compounds in marijuana that have been used for centuries as natural medicines and therapeutics. Cannabis is a known anti-inflammatory, containing antioxidants and anti-aging elements, while hemp seed oil contains both omega-3 and omega-6 fatty acids.

In spite of vast anecdotal evidence, science has not yet definitively settled on the positive effects of CBD skin care. However, the recent article “The Role of Cannabinoids in Dermatology,” published in the prestigious Journal of American Academy of Dermatology, suggests efficacy in CBD use for the treatment of several dermatologic conditions, including pruritus, inflammatory skin disease and skin cancer (http://nnw.fm/mXI9m). It’s likely that even more beneficial effects will be found.

Further scientific validation will be icing on the cake for ChineseInvestors.com, Inc. (OTCQB: CIIX). With the introduction of its line of cannabidiol-based skin care products, CIIX is primed and fast moving into the multi-billion dollar Chinese skin care industry. The company has already filed a record of its first line of hemp-infused skin care products with the China Food and Drug Administration and expects to launch it in the next couple months. As the company stated in a recent press release, “Although ancient Chinese recognized the medicinal properties of the cannabis plant, CBD extract appears to be largely unrecognized in China today for its benefits, including but not limited to, its potential benefits to the largest visible human organ, the skin.”

China is the second-largest consumer of skin care products in the world and generates nearly $30 billion in annual retail sales. Since no other notable manufacturers have entered the cannabis skin care product market in China, CIIX would be first to market and anticipates capturing “100% of China’s market share in this novel skin care products category.” The market potential is immense.

To facilitate and expedite market dominance, CIIX recently appointed skin care industry veteran and Shanghai beauty influencer Fannie (Chun Fang) Tang as marketing director of its wholly-owned CBD Biotechnology Co., Ltd. enterprise. Well known in China, Tang will be responsible for developing and implementing branding strategies for the company’s CBD Magic Hemp Series skin care line (http://nnw.fm/TMy1e).

Tang has proven success in the industry, bringing more than two decades of industry experience and previously serving as the CEO of L.D. Waxson, a leading skin care company with a footprint throughout China and much of Southeast Asia. Moving from CEO to director of marketing is a strong testament to the opportunity. There’s little doubt that with Tang’s experience, guidance and industry connections, CBD Biotechnology will position itself to become a leader in China’s skin care industry.

For more information, visit the company’s website at www.ChineseInvestors.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, October 16th, 2017 Uncategorized Comments Off

$MARK 3D Augmented Reality Chosen for Sina Weibo’s New Mobile App

LAS VEGAS, Oct. 13, 2017 — Remark Holdings, Inc. (NASDAQ: MARK), a global digital media technology company, announced that Sina Weibo, one of the world’s largest social media companies, is launching its first augmented-reality-enabled mobile application, named SuiShouPai (which means “take a picture anywhere, anytime”).  Remark Holdings’ KanKan subsidiary implemented SuiShouPai’s core augmented-reality feature using KanKan’s 3D facial-feature-tracking technology.

By choosing KanKan’s AI technology, Sina Weibo is using one of the world’s most advanced 3D facial-feature-tracking technologies, which makes the best mobile 3D augmented reality possible.  KanKan’s software, which was developed over the last several years using millions of globally-sourced facial feature samples, can precisely recognize and track the movements of hundreds of different facial features. The additional samples made available through SuiShouPai will enable KanKan’s facial-recognition technologies to better understand various facial expressions by improving the underlying AI’s ability to learn human emotions based on changes in facial features.

“We not only created a facial tracking system that we believe is far superior to existing technologies, but we also created 3D filters that can be used socially among friends or used to identify business opportunities in various industries, such as in the cosmetics field,” said Kai-Shing Tao, Remark Holdings’ Chairman and CEO.

“Our contract with Sina Weibo continues to demonstrate that we are able to monetize our artificial-intelligence technology, including facial and object recognition,” said Tao.  An example of how the technology functions can be found here.

Remark Holdings uses “deep learning”, a type of algorithm-based machine learning that is used to model high-level abstractions in data, to train its artificial intelligence products.  Utilizing KanKan’s extensive data sets to train its KanKan Artificial Intelligence Platform with tens of millions of supervised and unsupervised samples allows Remark Holdings to develop models that extract facial features and recognize objects, such as branded logos, animals or license plates, with a high degree of precision.

The KanKan Artificial Intelligence Platform is designed as a one-stop shop that will provide small to large enterprises and developers with the ability to customize and train their own artificial-intelligence models for their businesses, with stable and ready-to-use artificial-intelligence modeling stacks and pre-trained models.

 

About Remark Holdings, Inc.
Remark Holdings, Inc. (NASDAQ: MARK) primarily focuses on the development and deployment of artificial-intelligence-based solutions for businesses and software developers in many industries.  Additionally, the company owns and operates digital media properties that deliver relevant, dynamic content. The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Chengdu and Hangzhou, China. For more information, please visit the company’s website at www.remarkholdings.com.

Investor Relations Contact:
Douglas Osrow
Remark Holdings, Inc.
dosrow@remarkholdings.com
702-701-9514 ext. 3025

Friday, October 13th, 2017 Uncategorized Comments Off

$PZRX Announces Corporate Restructuring and Review of Strategic Alternatives

SEATTLE, Oct. 13, 2017  – PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its board of directors has made a determination to conduct a restructuring of operations to reduce short term operating costs and delay the development of its lead product candidate PRX-OTC. This reorganization includes a reduction in PhaseRx’s workforce by 10 employees, including some executive officers. These efforts are aimed at preserving the company’s cash resources. As of June 30, 2017, PhaseRx had cash and equivalents of $8.4 million and a total of 20 employees.

The board of directors has also begun a review of strategic alternatives, including but not limited to a potential merger transaction. The company has not set a timetable for this process. No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic alternatives will result in a transaction, or the terms or timing of any potential transaction that may take place.

The company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or otherwise determined that further disclosure is appropriate.

About PhaseRx

PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body’s inability to remove ammonia from the blood with potentially devastating consequences for patients. The company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.

Safe Harbor Statement

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the fact that the company has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future, (ii) the company being dependent on technologies it has licensed and that it may need to license in the future, (iii) the fact that the company will need to raise substantial additional funding to develop its planned products, (iv) the fact that the company’s Hybrid mRNA Technology has not previously been tested beyond company preclinical studies, and that mRNA-based drug development is unproven, (v) the fact that all of the company’s programs are in preclinical studies or early stage research and it is uncertain that any company product candidates will receive regulatory approval or be commercialized, (vi) the fact that development of the company’s product candidates will be expensive, time-consuming and subject to regulatory approval, (vii) the company expecting to continue to incur significant research and development expenses, (viii) the company becoming dependent on collaborative arrangements for the development and commercialization of its products, (ix) the company’s ability to adequately protect its proprietary technology from legal challenges, infringement or alternative technologies and (x) the biotechnology and pharmaceutical industries being intensely competitive. More detailed information about the company and the risk factors that may affect the realization of forward looking statements is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the most recent annual report on Form 10-K and its quarterly reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts:
Corporate Communications Contact:
Jason Spark
Canale Communications
Senior Vice President
jason@canalecomm.com
619-849-6005

Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
robert.uhl@westwicke.com
858.356.5932

Friday, October 13th, 2017 Uncategorized Comments Off

$NETE Announces Growth in North America Transactions Solutions Segment

Electronic commerce and value-added integrated transaction volumes increased by 134% during the first half of 2017 over the same period in 2016

MIAMI, FL–(Oct 13, 2017) – Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale (POS), e-commerce and mobile devices, today reported significant growth in Unified Payments, its North America Transactions Solutions Segment division.

Total e-commerce volumes for the first half of 2017 increased by 33% from the first half of 2016. Transactions processed for the first half of 2017 increased by 34% over the same period in 2016. New e-commerce merchants for the first half of 2017 increased by 37% over the same period in 2016.

Total volumes for electronic commerce and value-added integrated services such as Aptito and Unified m-POS increased by 134% during the first half of 2017 over the same period in 2016. Transactions processed for the first half of 2017 increased by 84% over the same period in 2016. New merchants for the first half of 2017 increased by 43% over same period in 2016.

“Unified Payments continues gaining market-share by delivering competitive e-commerce, mobile point of sale and integrated value added services through easy-to-use technology such as Apple iOS and Android apps while providing exceptional customer service, technical support and fast merchant on-boarding,” commented Oleg Firer, Chief Executive Officer of Net Element. ”We are confident in our ability to continue executing our growth strategy and are excited about the Company’s future.”

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to whether the Company will be successful in its delisting appeal with Nasdaq, its expansion and growth endeavors and in entering into new partnerships; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are : (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
media@netelement.com
+1 (786) 923-0502

Friday, October 13th, 2017 Uncategorized Comments Off

$POLA Multi-Unit Purchase Order of DC Power Systems for Puerto Rico

Initial 57 Unit Purchase Order to be Shipped Over Next Two Weeks to Hurricane-Affected Telecom Sites on Puerto Rico

GARDENA, CA–(October 12, 2017) – Polar Power, Inc. (NASDAQ: POLA), a global provider of prime and backup DC power solutions, has received a multi-unit purchase order of its 15 kilowatt (kW) back-up diesel DC generator set from its new Tier-1 wireless carrier customer in the United States. The initial 57 units will be shipped over the next two weeks to hurricane-affected telecom sites on the island of Puerto Rico.

Hurricane Maria, which lingered over Puerto Rico for 10 days in early to mid-September, caused extensive destruction and a humanitarian crisis in the region. Of the 3.6 million people who reside on the island, the vast majority have no power. According to the FCC, 91% of cellular sites are out of service and according to Wired.com, of the 1,600 cellular sites, at least 1,300 are out of service. Of the four fiber-optic providers in Puerto Rico, one is mostly broken and one is completely down. Roughly 75 percent of fiber coverage, including cellular service, isn’t working, and neither is about 40 percent of the wired network.

“We are pleased to receive our first material, multi-unit purchase order with our newly signed Tier-1 wireless carrier customer in the United States,” said Polar Power CEO, Arthur Sams. “It comes at a time when over 3.5 million U.S. citizens are without some form of access to cellular phone or data to communicate with family and friends.

“We look forward to continuing our collaboration with all of our Tier-1 wireless carrier customers as we work together to provide solutions to aid in the redevelopment of Puerto Rico’s wireless networks. We’ve seen an increase in inbound RFP requests due to the recent hurricanes and look forward to working with our partners to implement innovative solutions to restore service to areas hardest hit by these natural disasters,” concluded Sams.

About Polar Power, Inc.
Gardena, California-based Polar Power, Inc. (NASDAQ: POLA), designs, manufactures and sells direct current, or DC, power systems, lithium battery powered hybrid solar systems for applications in the telecommunications market and, in other markets, including military, electric vehicle charging, cogeneration, distributed power and uninterruptable power supply. Within the telecommunications market, Polar’s systems provide reliable and low-cost energy for applications for off-grid and bad-grid applications with critical power needs that cannot be without power in the event of utility grid failure. For more information, please visit www.polarpower.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this press release including, without limitation, Polar Power’s expectation that its new customers will commence ordering products during the next two weeks and beyond; Polar Power’s belief that customers will make major purchases in the fourth quarter of 2017; and Polar Power’s belief that RFP’s will turn into purchase orders are forward-looking statements and considerations that involve a number of risks and uncertainties. The actual future results of Polar Power could differ from those statements. Factors that could cause or contribute to such differences include, but are not limited to, adverse economic and market conditions, including demand for DC power systems; raw material and manufacturing costs; changes in governmental regulations and policies; and other events, factors and risks previously and from time to time disclosed in Polar Power’s filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Polar Power’s Form 10-Q/A filed with the Securities and Exchange Commission on July 11, 2017.

Media and Investor Relations:

Chris Tyson
Managing Director
MZ North America
Direct: 949-491-8235
ir@polarpowerinc.com
www.mzgroup.us

Company Contact:

Polar Power, Inc.
249 E. Gardena Blvd.
Gardena, CA 90248
Tel: 310-830-9153
ir@polarpowerinc.com
www.polarpower.com

Thursday, October 12th, 2017 Uncategorized Comments Off

$AMPE Accepted Publication of Pooled Ampion™ Clinical Results in Severe Osteoarthritis

ENGLEWOOD, Colo., Oct. 12, 2017 – Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: “LMWF-5A For The Treatment Of Severe Osteoarthritis Of The Knee: Integrated Analysis Of Safety And Efficacy” was accepted for publication in Orthopedics, an international peer-reviewed journal in the field of Orthopedics. Ampion™ is the Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A).

Ampio’s Chief Scientific Officer, Dr. David Bar-Or described the study as follows: “This was a combined analysis of all completed single-injection Ampion™ randomized placebo-controlled trials to date, focusing on the subset of patients with severe (Kellgren-Lawrence [KL] grade 4) osteoarthritis of the knee (OAK). The objective of the study was to examine the safety and efficacy of an intra-articular injection of Ampion™ compared to a saline placebo control in patients with severe OAK. Safety and efficacy measurements, subject eligibility, treatment, randomization and blinding, were identical across all trials.”

Dr. Brian Cole, who co-authored the article, explained, “417 patients is thought to be the largest study treating the KL grade 4 population to be published. This pooled analysis demonstrated that a single-injection of Ampion™ was safe and well tolerated across all trials. Patients treated with Ampion™ were also significantly more likely to respond to treatment and with a longer duration of response as compared to saline. These results are clinically important and provide support for Ampion™ for the indication of pain due to severe OAK. The KL grade 4 population is an unmet medical need.”

Ampion™ is in late-stage development to treat the signs and symptoms of severe OAK. Based on FDA guidance, Ampio recently completed enrollment in the 12-week pivotal trial of Ampion™, which enrolled patients with severe OAK (KL grade 4) to evaluate the efficacy of Ampion™ for the treatment of pain, function, and Patient Global Assessment (PGA). The primary study endpoint is the OMERACT-OARSI responder criteria.

About Osteoarthritis
Osteoarthritis (OA) is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. The incidence of developing osteoarthritis of the knee over a lifetime is approximately 45%. As this disease is associated with age, obesity, and diabetes, this number will continue to grow. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward-Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s scientific publications on our Ampion™ product. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Tom Chilcott
Chief Financial Officer
Phone: (720) 437-6500
tchilcott@ampiopharma.com

Thursday, October 12th, 2017 Uncategorized Comments Off

$INFI Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting

- Clinical and Translational Data from Monotherapy Dose-Escalation Component of Ongoing Phase 1/1b Study of IPI-549 in Patients with Advanced Solid Tumors to be Reported During an Oral Session -

CAMBRIDGE, Mass., Oct. 12, 2017  – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that an abstract describing new data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), has been selected as a late-breaking presentation during an oral session at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD, November 10 – 12. Additionally, a clinical trials in progress poster will also be presented on the Phase 1/1b clinical study which is ongoing to explore the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo® (nivolumab), a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors. IPI-549 is believed to be the only PI3K-gamma inhibitor in clinical development.

Details of the presentations are as follows:

Updated Phase 1/1b Data
Title: Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages
Abstract number: O43
Oral session: Clinical Trials – New Agents
Oral session date and time: Friday, November 10, 2017, from 1:45 p.m. –3:30 p.m. ET
Lead author: David Hong, M.D., Deputy Chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Additionally, an identically titled poster will be presented on Friday, November 10, 2017, from 12:30 p.m. – 2:00 p.m. ET and 6:30 p.m. – 8:00 p.m. ET.

Clinical Trials in Progress
Title: Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
Abstract number: P219
Poster session: Clinical trials in progress
Presentation time: Friday, November 10, 2017, from 12:30 p.m. – 2:00 p.m. ET and 6:30 p.m. – 8:00 p.m. ET
Lead author: Antoni Ribas, M.D., Ph.D., Parker Institute Center Director at the University of California, Los Angeles (UCLA)

About the IPI-549 and the Ongoing Phase 1 Study
IPI-549 is an investigational, orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. In preclinical studies, IPI-549 reprograms macrophages from a pro-tumor, M2, to an anti-tumor, M1, phenotype and is able to overcome resistance to checkpoint inhibition as well as to enhance the activity of checkpoint inhibitors.1,2 As such, IPI-549 may have the potential to treat a broad range of solid tumors and represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors.

A Phase 1 study of IPI-549 in patients with advanced solid tumors is ongoing to evaluate the safety, tolerability, activity, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy and in combination with Opdivo in approximately 200 patients with advanced solid tumors.3 The four-part study includes monotherapy and combination dose-escalation components, in addition to monotherapy expansion and combination expansion components. Patient enrollment is complete in monotherapy dose-escalation, and monotherapy expansion is ongoing. Combination dose-escalation is also ongoing, and combination expansion is expected to begin in the second half of 2017.

The combination expansion component includes multiple cohorts designed to evaluate IPI-549 in patients with specific types of cancer, including patients with non-small cell lung cancer (NSCLC), melanoma, and head and neck squamous cell carcinoma (HNSCC) whose tumors show initial resistance or subsequently develop resistance to immune checkpoint blockade therapy. This combination expansion will also include a cohort of patients with triple negative breast cancer (TNBC) who have not been previously exposed to immune checkpoint blockade therapy. Although there has been great progress in the treatment of cancer, there remains a need for additional treatment options. NSCLC, melanoma, HNSCC and TNBC account for more than 22 percent of all new cancer cases in the U.S.4,5

IPI-549 is an investigational compound and its safety and efficacy has not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity’s website at www.infi.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including those regarding the company’s expectations about the timing and type of data presentations, the therapeutic potential of PI3K-gamma inhibition and of IPI-549, alone or in combination with other agents, and clinical trial plans regarding IPI-549. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations, including, for example, that there is no guarantee that IPI-549 will successfully complete necessary preclinical and clinical development phases, or gain regulatory approval, and other risks described in greater detail under the caption “Risk Factors” included in Infinity’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 3, 2017, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

OPDIVO® is a registered trademark of Bristol-Myers Squibb.

Contact:
Jaren Irene Madden, Senior Director, Investor Relations and Corporate Communications
617-453-1336 or Jaren.Madden@infi.com

____________________________

1
Kaneda, M., Messer, K., Ralainirina, N., Li, H., et al. PI3Kγ is a molecular switch that controls immune suppression. Nature, 2016 Nov;539:437-442.
2 De Henau, O., Rausch, M., Winkler, D., Campesato, L., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature, 2016 Nov;539:443-447.
3 www.clinicaltrials.gov, NCT02637531.
4 American Cancer Society, Cancer Facts and Statistics 2017, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/index and http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics, Last Accessed September 19, 2017.
5 Conquer Cancer Foundation, Head and Neck Cancer Statistics, http://www.cancer.net/cancer-types/head-and-neck-cancer/statistics, Last Accessed September 19, 2017.

Thursday, October 12th, 2017 Uncategorized Comments Off

$STLHF NetworkNewsWire Releases Exclusive Audio Interview

NEW YORK, NY–(Oct 12, 2017) – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with Standard Lithium Ltd. (TSX VENTURE: SLL) (FRANKFURT: S5L) (OTCQX: STLHF), a Canadian-based energy exploration and development company building one of the largest portfolios of high-quality lithium brine assets in the United States.

The interview can be heard at http://NNW.fm/STLHF-October-2017

Standard Lithium CEO and Director Robert Mintak shares company news and insights with NNW’s Stuart Smith in an interview that delves into the opportunities presented by the world’s changing energy demands.

“I’ve been working in the lithium sector for the better part of the last decade, and the team that has joined me has been working extensively in the lithium space as well, at the cutting edge of new lithium processing technologies,” Mintak says. “We’ve been at the forefront of applying new technologies and new processing applications to really look at unlocking resources that haven’t been viewed through the right lens.”

Standard Lithium has partnered with National Chloride Corporation of America at its Bristol Lake project in San Bernardino County, California. Everything about the 25,000-plus acre project fit nicely into the company’s criteria, Mintak says, pointing out the area has seen almost a century of industrial mineral production from brines.

“We’re able to immediately begin working on the important processing work that any lithium project has to do,” he says. “Lithium projects aren’t traditional mining projects, they’re more chemistry projects.”

Standard Lithium’s team of experts is bringing an enviable amount of extremely valuable experience in the resource development and processing side of the lithium space. The company’s drive to provide battery-grade lithium materials is buoyed by a belief in the transformative state of the world’s energy marketplace.

“We’re at the early stages of a new economy and lithium is at the heart of that economy,” Mintak says. “It’s all about energy storage now with the adoption of electric vehicles just starting to take hold. We’re seeing news coming out of China, saying they’re looking at banning internal combustion engines, and we’ve heard similar stories coming out of England and France. That’s going to mean a massive demand for lithium.”

The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

“We believe it’s going to exceed that, so the lithium space, the electric metal space, is one of the most attractive and exciting spaces to be in for a mining, mineral exploration company,” Mintak concludes.

About Standard Lithium Ltd.

Standard Lithium Ltd. (TSX VENTURE: SLL) (FRANKFURT: S5L) (OTCQX: STLHF), is a Canadian-based energy exploration and development company with a value-driven strategy of acquiring a diverse and highly prospective portfolio of large-scale domestic lithium-bearing brine resources. Led by an innovative and results-oriented management team with a strong focus on technical skills, Standard Lithium is currently focused on the exploration of its Bristol Lake Brine Project in the Mojave region of San Bernardino County, California.

For more information, visit www.StandardLithium.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact

Thursday, October 12th, 2017 Uncategorized Comments Off

$IMNP Announces Presentation at The Liver Meeting 2017

ENGLEWOOD CLIFFS, N.J.

Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic effect of oral and parenteral administration of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis will be presented at The Liver Meeting 2017 – the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, DC. Dr. Yaron Ilan, Professor of Medicine, and Director, Department of Medicine at Hebrew University’s Hadassah Hospital in Jerusalem, Israel, and an Immune Pharmaceuticals collaborator, will present the data in a poster.

The poster (#350), entitled “Oral administration of anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel personalized therapy for immune-associated liver diseases” (#350) will be presented Friday, October 20 between 12:00 and 1:30 PM ET at the “Autoimmune and Cholestatic Liver Disease” session. The study aimed to evaluate the biological activity and immunomodulatory effect of oral and parenteral administration of anti-eotaxin-1 antibodies in the concanavalin A (ConA) mouse model of immune hepatitis. Anti-eotaxin-1 antibodies, administered two hours prior to the induction of hepatitis, lowered eotaxin-1 levels and prevented the development of hepatitis compared to controls.

Dr. Ilan commented, “These experiments showed that blocking eotaxin-1 can have a profound impact on the development of hepatic inflammation. Anti-eotaxin-1 antibodies lowered eotaxin-1 levels and were effective at blocking liver injury whether administered parenterally or orally. These results have obvious implications for the potential use of bertilimumab in liver diseases in which chronic inflammation plays a role, including NASH.”

Elliot Maza, President and Chief Executive Officer of Immune Pharmaceuticals, stated, “Our collaboration with Dr. Ilan has been fruitful and yielded results suggesting that blocking eotaxin-1 can have a beneficial effect in liver diseases. We will continue to explore the development of bertilimumab in liver diseases, further to our strategic business plan of focusing our resources on this first-in-class antibody.”

About Immune Pharmaceuticals

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, we are conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including NASH, atopic dermatitis, immune and inflammatory hepatitis, and asthma.

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this news release made by representatives of Immune Pharmaceuticals, Inc. relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune’s product candidates and the sufficiency of Immune’s cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune’s ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that the Company will ever successfully complete its anticipated corporate restructuring, or that the Company will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. The Company may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune’s board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune’s filings with the Securities and Exchange Commission, including those discussed in Immune’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q periodic reports filed on Form 8-K.

 

Immune Pharmaceuticals Inc.
Elliot Maza
investors@immunepharma.com

Wednesday, October 11th, 2017 Uncategorized Comments Off

$AKTX Announces Further Clinical Progress

  • Completion of enrollment into COBALT, the Phase II PNH trial of Coversin™

NEW YORK and LONDON, Oct. 11, 2017  — Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, announces that three additional patients have been enrolled in the ongoing Phase II COBALT clinical trial of Coversin™ in patients with paroxysmal nocturnal hemoglobinuria (PNH).

COBALT, the Phase II 90-day, open label single arm clinical trial, has enrolled a total of eight patients, four of whom have completed the trial and were reported on at the European Hematology Association conference in June 2017.  These four patients have all moved into Akari’s long-term safety study, CONSERVE.  One of the initial five patients enrolled in the COBALT trial, with a suspected co-morbidity unrelated to the treatment, was withdrawn from the study on day 43.

Three new patients were enrolled pursuant to an amended protocol based on a revised dosing regimen which included changing the maintenance phase from a single dose of 30mg every 24 hours to a single dose of 45mg every 24 hours. The three newly enrolled patients on the revised dosing regimen have now completed approximately 8, 3 and 2 weeks, respectively. The primary endpoint in this clinical trial is reduction in serum LDH (lactate dehydrogenase; an indication of hemolysis) to ≤1.8 times the ULN (upper limit of normal) for the investigator’s reference laboratory or 500 I U/L, whichever is the lower from day 1 (pre-dose) to day 28.  The first of the three patients had a LDH value of 1.5 times the ULN at day 28.  The other two patients have not yet reached the primary endpoint measurement date.  To date, there have been no drug-related serious adverse events.  The data reported is taken from the current electronic case report forms.

Akari plans to provide an update on all PNH patients currently enrolled at the American Society of Hematology Annual Meeting to be held December 9-12, 2017.

Akari plans to advance Coversin towards Phase III clinical trials beginning with CAPSTONE in Q1 2018, a Phase III clinical trial of Coversin in naïve PNH patients.

About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari’s lead drug candidate Coversin is a C5 complement inhibitor currently being evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory activity, Coversin independently and specifically inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin in two conditions, the skin and eye diseases bullous pemphigoid and atopic keratoconjunctivitis, where the dual action of Coversin on both C5 and LTB4 may be beneficial. Akari is also developing other tick derived proteins, including long acting versions.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, an inability or delay in obtaining required regulatory approvals for Coversin and any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 20-F filed on March 31, 2017. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:

Peter Vozzo
Westwicke Partners
(443) 213-0505
peter.vozzo@westwicke.com

Media Contact:

Mary-Jane Elliott / Sukaina Virji
Consilium Strategic Communications
+44 (0)20 3709 5700
Akari@consilium-comms.com

Wednesday, October 11th, 2017 Uncategorized Comments Off